VM Life Science

VM Pharma is a clinical-stage biopharmaceutical company focused on developing first-in-class small molecule therapeutics for the treatment of pain, inflammation, and oncology. The company's lead program, VM-902 (also known as ONO-7579), is a highly selective, orally bioavailable pan-Trk inhibitor designed to address chronic pain conditions such as osteoarthritis and neuropathic pain. By targeting the tropomyosin receptor kinase (Trk) family, VM Pharma aims to provide potent analgesic effects while minimizing the side effects associated with traditional pain medications. The company operates as part of a virtual development model, leveraging strategic partnerships to advance its pipeline through clinical proof-of-concept.